Markets declined due to global and domestic pressures, with the Nifty testing support at 25040. Glenmark Pharma partnered with Hengrui Phar...

The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir - a t...

Indian drugmakers, Dr Reddy's and Hetero Labs, will offer generic HIV prevention drugs. The price will be around $40 yearly from 2027. This...

The WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 202...

South Africa faces setbacks in HIV research. The United States withdrew funding, impacting trials. Researchers are devastated as crucial pr...

A twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by mid-2026. Develope...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hail...

Despite global turmoil, 2024 saw groundbreaking scientific advancements, including discovering the moon's far side, a new HIV prevention dr...

Gilead's twice-yearly HIV prevention shot was 100% effective in women and almost as good in men. The company will offer cheap generic versi...

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, ha...

Lenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears Gilead's patent ...

The shots made by U.S. drugmaker Gilead and sold as Sunlenca are approved in the U.S., Canada, Europe and elsewhere, but only as a treatmen...

A new "vaccine-like" HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated...

The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs,...